Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Condition:   Treat and Extend Regimen
Interventions:   Drug: Ranibizumab 0.5mg;   Drug: Ranibizumab 0.5mg
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting – verified September 2013

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




eighteen − 3 =